Synapsica Healthcare
Winter 2020InactiveAI-enabled automation of diagnostic radiology workflow and reporting.
Pressure-test this opportunity
Turn this teardown into a decision-ready prompt for ChatGPT, Claude, or your agent.
AI-enabled automation of diagnostic radiology workflow and reporting.
Turn this teardown into a decision-ready prompt for ChatGPT, Claude, or your agent.
If you only have a few minutes to spare, here’s what investors, operators, and founders should know about Synapsica Healthcare (W20).
Synapsica Healthcare built AI-assisted radiology software that combined image management, measurement, reporting, and back-office workflow. Its flagship RadioLens product reached an important regulatory milestone: FDA cleared version 1.0 as Class II medical image management and processing software in March 2023.
The company's public record also contains a governance crisis. Police arrested two founders in September 2022 after a former partner accused them of share-related fraud. Those claims were allegations, not a finding of guilt. The next month, Synapsica cut nearly 30 jobs. Y Combinator now marks the company inactive, but no shutdown notice, buyer, terminal date, transaction terms, or final court disposition was found.
Cherian Dr, Gandharv Goyal, Kuldeep Singh Chauhan, and Meenakshi Singh founded Synapsica in 2018. The team entered YC's Winter 2020 batch with a broad pitch: automate diagnostic radiology workflow and reporting.
Their product thesis was narrower than "AI reads scans." Radiologists spend time on measurements, repeated descriptions, image selection, and report assembly. Synapsica sought to turn those steps into structured software while leaving clinical judgment with the physician.
RadioLens joined a radiology worklist with tools for image review, quantitative measurements, illustrated findings, and report creation. The 2021 product description emphasized spine-related pathology and reports that showed the location and extent of findings.
Synapsica also promoted an AI-first picture archiving and communication system and related tools for spine MRI, stress X-ray, chest X-ray, and head CT work. Public sources do not establish which modules remained commercially available or how many sites used them.
FDA's 2023 decision covered RadioLens v1.0 as medical image management and processing software. Clearance permitted marketing under applicable controls; it did not validate every product claim or establish clinical adoption.
Synapsica sold to radiologists, imaging centers, hospitals, and specialists who wanted faster, more consistent reporting. A useful deployment had to fit existing image archives and worklists without slowing review or obscuring source images.
The company operated inside the large radiology IT market, but the reviewed sources do not support a precise serviceable market. The practical market depended on modality coverage, geography, regulatory clearance, integrations, and the number of studies a customer could route through the system.
Synapsica competed with established PACS and reporting vendors, specialist radiology-AI companies, and internal hospital workflows. Its pitch connected AI measurements to the reporting experience. The harder task was earning clinical trust while supporting integrations, regulation, security, and sales across many institutions.
The likely model was enterprise software sold to imaging providers, with contracts tied to sites, users, or study volume. Public sources do not disclose pricing, gross margin, renewal rates, customer concentration, or revenue.
Synapsica raised $4.2 million in its 2021 Series A from IvyCap Ventures, Endiya Partners, YC, and angels. CB Insights reports $4.36 million raised in total. The round was intended to support overseas expansion and a broader set of AI features.
The record does not support a clean shutdown story. It supports a sequence of acute strain: a dispute among founders, police allegations against two executives, a roughly 30% workforce cut, and then an FDA clearance six months later. The product milestone after the arrests matters because it rules out the simplest claim that work stopped immediately.
Read the complete post-mortem, the rebuild playbook, and the exact reasons Synapsica Healthcare is still worth studying now.